---

title: Tesamorelin (GHRH Analog): A Synthetic GRF 1–44 Analogue description: "Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH, also known as GRF 1–44) with a single norleucine substitution at position 27 that confers enhanced metabolic stability. FDA-approved for HIV-associated lipodystrophy, it reduces visceral adipose tissue by 15–20% and is under investigation for NASH, sarcopenia, and cognitive function." date: 2025-07-15

---

Tesamorelin (GHRH Analog): A Synthetic GRF 1–44 Analogue

Quick Facts

Full Name	Tesamorelin (INN); TH9507 (developmental code)
Class	Synthetic growth hormone-releasing hormone (GHRH) analog / GRF 1–44 analogue
Molecular Formula	C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight	~5,135 Da
Amino Acid Length	44 amino acids
Mechanism	GHRH receptor agonist; stimulates pulsatile pituitary GH secretion
Sequence Homology	Identical to endogenous human GHRH (1–44) with Nle27 substitution for Met27
Route of Administration	Subcutaneous injection
Regulatory Status	FDA-approved (Egrifta) for HIV-associated lipodystrophy (2010)
PubChem CID	16135177
CAS Number	948594-65-8

Executive Summary

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), also referred to as growth hormone-releasing factor (GRF) 1–44. It differs from endogenous GHRH by a single amino acid substitution — norleucine (Nle) replacing methionine (Met) at position 27 — which confers resistance to oxidative degradation and dipeptidyl peptidase-4 (DPP-IV)-mediated proteolytic cleavage.

Tesamorelin acts as a selective GHRH receptor (GHRHR) agonist on pituitary somatotroph cells, stimulating the pulsatile release of endogenous growth hormone (GH). Crucially, this mechanism preserves the natural ultradian rhythm of GH secretion — characterized by 6–10 discrete secretory pulses per 24 hours — distinguishing it fundamentally from exogenous recombinant human GH (rhGH) administration, which delivers a sustained, supraphysiological, non-pulsatile hormone profile.

In 2010, tesamorelin received FDA approval under the brand name Egrifta for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy, a condition characterized by visceral fat accumulation, peripheral lipoatrophy, insulin resistance, and dyslipidemia associated with antiretroviral therapy. Pivotal phase III trials demonstrated 15–20% reductions in visceral adipose tissue (VAT) over 26 weeks, with preservation of subcutaneous adipose tissue (SAT) — a critical distinction from the non-selective lipolytic effects of supraphysiological GH therapy. Ongoing research investigates tesamorelin's applications in metabolic dysfunction-associated steatohepatitis (MASH), sarcopenia, cognitive function, and cardiovascular risk reduction. For researchers, tesamorelin provides a unique tool for studying the somatotropic axis and the metabolic consequences of restoring physiological GH pulsatility in states of relative GH deficiency.

Background

Growth hormone-releasing hormone (GHRH) is a hypothalamic peptide that serves as the primary positive regulator of the somatotropic axis, stimulating both the synthesis and pulsatile secretion of growth hormone from anterior pituitary somatotroph cells. In 1982, Rivier and colleagues at the Salk Institute first isolated and characterized human GHRH from pancreatic tumors causing acromegaly — a landmark discovery that identified both the 44-amino-acid (GHRH 1–44) and 40-amino-acid (GHRH 1–40) isoforms. The 1–44 isoform was subsequently established as the predominant circulating form possessing full biological activity. Structurally, GHRH belongs to the glucagon/secretin superfamily of peptides and signals through the GHRH receptor (GHRHR), a class B G protein-coupled receptor.

Native GHRH has a short plasma half-life (approximately 5–10 minutes) due to rapid proteolytic degradation by DPP-IV, which cleaves at the Ala2-Asp3 bond, and by other serum and tissue peptidases. This pharmacokinetic limitation, combined with the requirement for pulsatile delivery to maintain physiological GH secretion patterns, had historically constrained the therapeutic application of GHRH peptides.

Tesamorelin was developed to overcome these limitations. The strategic substitution of norleucine — a non-proteinogenic amino acid with a straight-chain hydrocarbon side chain — for methionine at position 27 conferred resistance to oxidative degradation (methionine is susceptible to sulfoxide and sulfone formation under physiological oxidizing conditions) and DPP-IV recognition while fully preserving receptor-binding affinity and GHRHR activation potency. The development program, conducted by Theratechnologies, was anchored by the recognition that HIV-infected patients on antiretroviral therapy frequently exhibit a state of relative GH deficiency characterized by reduced GH pulse amplitude, decreased IGF-1 levels, and a lipodystrophy syndrome of excess visceral adiposity and ectopic fat deposition.

Core Science

GHRH Receptor Signaling

Tesamorelin binds selectively and with high affinity to the GHRH receptor (GHRHR), a class B (secretin family) GPCR expressed predominantly on somatotroph cells of the anterior pituitary gland. GHRHR is also expressed at lower levels in extrapituitary tissues including immune cells, pancreatic islets, and certain tumor cell types, though the functional significance of extrapituitary expression remains under investigation.

Upon tesamorelin binding to the extracellular N-terminal domain of GHRHR, the receptor undergoes conformational rearrangement that activates intracellular Gαs-mediated adenylyl cyclase signaling, producing a rapid increase in cyclic AMP (cAMP). The cAMP–PKA signaling cascade serves two complementary functions in somatotroph cells: (1) acute stimulation — PKA-mediated phosphorylation triggers exocytosis of pre-formed GH-containing secretory granules, releasing GH into the systemic circulation within minutes; and (2) chronic stimulation — PKA-mediated phosphorylation of the transcription factor CREB (cAMP response element-binding protein) at Ser133 enhances GH gene transcription and new GH protein synthesis, maintaining the releasable GH pool across repeated stimulations.

Downstream, GH secreted from the pituitary binds to GH receptors (GHR) expressed ubiquitously but most abundantly in the liver, where receptor activation stimulates JAK2-STAT5 signaling and hepatic insulin-like growth factor 1 (IGF-1) synthesis and secretion. IGF-1, in turn, mediates many of the peripheral anabolic and metabolic effects of GH, including stimulation of protein synthesis, lipolysis, and linear growth. The GH–IGF-1 axis is subject to negative feedback regulation: elevated IGF-1 levels suppress GHRH secretion from the hypothalamus and directly inhibit GH secretion at the pituitary level, creating a homeostatic regulatory loop that maintains physiological GH and IGF-1 levels within narrow ranges.

Pulsatile GH Secretion — A Critical Distinction

A defining feature of tesamorelin's mechanism, with profound implications for its metabolic effects and safety profile, is the preservation of physiological pulsatile GH secretion. Endogenous GH secretion is not continuous but occurs in discrete pulses (6–10 per 24 hours) separated by prolonged trough periods of near-undetectable GH levels. This ultradian rhythm is generated by the interplay of hypothalamic GHRH (stimulatory) and somatostatin (inhibitory) secretion, with the majority of GH secreted during slow-wave sleep.

Tesamorelin, by acting as a GHRHR agonist at the pituitary level, amplifies the amplitude of endogenous GH pulses without disrupting the underlying rhythmicity. This stands in fundamental contrast to exogenous rhGH administration, which delivers supraphysiological GH levels in a sustained, non-pulsatile pattern that bypasses normal regulatory feedback mechanisms.

The physiological significance of GH pulsatility has been elucidated through comparative studies using continuous versus pulsatile GH infusion models. Pulsatile GH is more effective than continuous GH in: (1) stimulating hepatic IGF-1 production (pulsatile GH achieves higher IGF-1 levels at equivalent total GH exposure); (2) promoting lipolysis in adipose tissue; (3) stimulating longitudinal bone growth; and (4) maintaining hepatic GH receptor expression (continuous GH infusion downregulates GHR through ligand-induced internalization). Conversely, continuous high-dose GH exposure more frequently produces adverse effects including hyperglycemia (through GH-mediated insulin resistance), fluid retention, and arthralgias. The preservation of pulsatility with tesamorelin may therefore offer a more favorable therapeutic index — enhanced metabolic efficacy with reduced adverse effects — compared to exogenous GH therapy.

Impact on Body Composition

The effects of tesamorelin on body composition in HIV-associated lipodystrophy are characterized by selective reduction of visceral adipose tissue (VAT) with relative preservation of subcutaneous adipose tissue (SAT). In the pivotal phase III trials by Falutz and colleagues, tesamorelin 2 mg daily reduced VAT by 15–20% over 26 weeks as measured by CT at the L4–L5 level, compared to no significant change with placebo. This selective effect on VAT — as opposed to the generalized lipolytic effect of supraphysiological GH — is believed to reflect the greater sensitivity of visceral adipocytes to GH-mediated lipolysis compared to subcutaneous adipocytes, combined with the preservation of physiological GH pulsatility that avoids the sustained GH elevations that drive generalized lipolysis.

Importantly, the reduction in VAT was accompanied by improvements in metabolic parameters including reductions in triglycerides, total cholesterol-to-HDL ratio, and visceral adiposity-associated inflammatory markers. The preservation of SAT is clinically meaningful, as peripheral lipoatrophy in HIV patients is itself associated with insulin resistance and metabolic dysfunction.

Hepatic Effects

Tesamorelin has demonstrated significant effects on hepatic steatosis. In a randomized, placebo-controlled trial by Stanley and colleagues, 12 months of tesamorelin treatment in HIV-infected patients with NAFLD resulted in a 37% relative reduction in liver fat content measured by proton magnetic resonance spectroscopy (¹H-MRS), compared to a 5% increase in the placebo group. This was accompanied by significant reductions in serum ALT and AST levels, indicating improvement in hepatic inflammation. Fourman and colleagues subsequently extended these findings, demonstrating that tesamorelin also reduced markers of hepatic fibrosis in a post-hoc analysis, suggesting effects beyond steatosis alone.

The mechanism of hepatic fat reduction likely involves both direct GH receptor-mediated effects on hepatocyte lipid metabolism (stimulation of fatty acid β-oxidation, inhibition of de novo lipogenesis) and indirect effects through reduced adipose tissue lipotoxicity and improved systemic insulin sensitivity. Of note, subgroup analyses indicated that the reduction in liver fat was independent of changes in visceral adiposity, pointing to direct hepatic actions of GH axis stimulation rather than secondary effects of VAT reduction.

Pharmacological Properties

Tesamorelin is administered as a subcutaneous injection (2 mg once daily) into the abdomen. Following administration, peak plasma concentrations are reached within approximately 1–2 hours, with a terminal elimination half-life of approximately 26–38 minutes in patients with HIV. Despite this relatively short half-life, once-daily administration is sufficient to amplify the amplitude of endogenous GH secretory pulses occurring within the dosing window, with GH levels returning to trough between doses. The peptide is primarily eliminated through renal clearance and proteolytic degradation. Oral bioavailability is negligible, consistent with its molecular weight (~5,135 Da) and peptide character.

Clinical Evidence

The pivotal phase III clinical program enrolled HIV-infected patients with antiretroviral therapy-associated lipodystrophy and excess abdominal fat accumulation. In the initial 26-week randomized, double-blind, placebo-controlled trials, tesamorelin 2 mg daily produced a 15.2% reduction in VAT (measured by CT) compared to a 5.0% increase in the placebo group. Long-term extension studies over 52 weeks confirmed durability of VAT reduction and demonstrated that treatment discontinuation led to gradual VAT re-accumulation, indicating the need for ongoing therapy.

The hepatic effects of tesamorelin have been investigated in dedicated trials. In patients with HIV-associated NAFLD, 12 months of treatment reduced hepatic fat fraction by 37% relative to placebo, with corresponding reductions in ALT and AST. The effects in non-HIV populations have been explored in preliminary studies: Makimura and colleagues demonstrated that tesamorelin reduces VAT in growth hormone-deficient adults, suggesting the metabolic benefits extend beyond the HIV population to other states of GH insufficiency.

Research Evidence

Finding	Data	Source
VAT reduction (phase III, 26 weeks)	−15.2% vs +5.0% placebo	N Engl J Med. (2007)
VAT reduction (52-week extension)	−17.5% sustained	AIDS. (2008)
Hepatic fat reduction (¹H-MRS, 12 months)	−37% relative vs +5% placebo	J Clin Endocrinol Metab. (2019)
ALT reduction (12 months)	−9.1 U/L vs −2.8 U/L placebo	Hepatology. (2020)
Triglyceride reduction (26 weeks)	−0.38 mmol/L vs +0.08 placebo	N Engl J Med. (2007)
IGF-1 increase (26 weeks)	+81 μg/L vs −5 μg/L placebo	N Engl J Med. (2007)
GH pulse amplitude (tesamorelin vs baseline)	2- to 3-fold increase	J Clin Pharmacol. (2009)
SAT preservation (26 weeks)	No significant change vs placebo	J Clin Endocrinol Metab. (2009)
VAT reduction in GH-deficient adults	−7.6% vs +2.3% placebo	J Clin Endocrinol Metab. (2018)
Fibrosis marker reduction (NAFLD)	Significant decrease in FIB-4 index	Hepatology. (2020)
Tesamorelin half-life (HIV patients)	26–38 minutes	J Clin Pharmacol. (2009)
DPP-IV resistance (Nle27 substitution)	>90% stability at 24h in vitro	Peptides. (2006)

FAQ

Q: What distinguishes tesamorelin from endogenous GHRH?

A: Tesamorelin differs from endogenous human GHRH (1–44) by a single amino acid substitution: norleucine (Nle) replaces methionine (Met) at position 27. Methionine is susceptible to oxidative degradation — its thioether side chain can be oxidized to methionine sulfoxide and sulfone under physiological conditions, reducing biological activity. Norleucine, with its straight-chain hydrocarbon side chain, is resistant to oxidation. Additionally, this substitution contributes to resistance against DPP-IV-mediated cleavage. Receptor binding and activation studies confirm that the Nle27 substitution preserves full GHRHR binding affinity and potency relative to native GHRH.

Q: Is tesamorelin a growth hormone secretagogue? How does it compare to GHS-R1a agonists?

A: Yes, tesamorelin is a growth hormone secretagogue, but it acts through the GHRH receptor on pituitary somatotroph cells, not the ghrelin receptor (GHS-R1a) targeted by compounds such as ipamorelin, GHRP-2, and GHRP-6. GHRH receptor agonists and ghrelin receptor agonists stimulate GH secretion through distinct receptor systems that generate synergistic GH responses when co-administered. Tesamorelin directly mimics endogenous GHRH, amplifying the amplitude of physiological GH pulses while preserving pulsatile rhythmicity. Ghrelin mimetics, by contrast, produce a more acute GH surge with somewhat different pharmacokinetics and potentially different effects on appetite (ghrelin is orexigenic, whereas GHRH is not directly appetite-modulating).

Q: What is the regulatory status of tesamorelin?

A: Tesamorelin (brand name Egrifta) received FDA approval in November 2010 for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. It also holds marketing authorization in Canada. The approved indication is specifically for HIV-associated lipodystrophy; tesamorelin remains an investigational compound for all other indications including MASH/NASH, sarcopenia, cognitive disorders, and general obesity. Phase II and III trials for MASH and other metabolic indications are ongoing, and label expansion would require positive results from these studies.

Q: Does tesamorelin affect blood glucose levels?

A: Clinical trials indicate that tesamorelin does not adversely affect glycemic control in patients with HIV-associated lipodystrophy. While GH is known to induce insulin resistance — primarily through stimulation of lipolysis, which increases circulating free fatty acids that antagonize insulin signaling — the degree of insulin antagonism with tesamorelin-stimulated endogenous GH appears modest. Some studies have reported improvements in insulin sensitivity attributable to the reduction in visceral adiposity and hepatic steatosis, which collectively improve metabolic health. However, as GH can induce transient insulin resistance, glucose monitoring is standard in clinical trials, and caution is warranted in patients with pre-existing diabetes.

Q: What are the most common adverse events?

A: The most frequently reported adverse events in clinical trials include: (1) injection-site reactions (erythema, pruritus, bruising) — the most common event, typically mild and self-limited; (2) arthralgias (joint pain) and myalgias (muscle pain) — consistent with GH-mediated effects on connective tissue and fluid balance; (3) peripheral edema — mild fluid retention, a known GH effect; and (4) paresthesias — mild sensory disturbances including carpal tunnel syndrome-like symptoms. These events are generally mild to moderate in severity and are consistent with the known effects of GH axis stimulation. Serious adverse events have been rare and not consistently attributed to study drug.

Q: Can tesamorelin be administered orally?

A: No. Like virtually all peptides of its size (44 amino acids, ~5,135 Da), tesamorelin undergoes rapid and complete proteolytic degradation in the gastrointestinal tract, resulting in negligible oral bioavailability. It is formulated exclusively for subcutaneous injection, administered once daily. The development of an oral GHRH analog would require substantial formulation innovation — potentially including absorption enhancers, enteric coatings, enzyme inhibitors, or carrier-mediated delivery systems — and no oral GHRH analog has reached clinical development to date.

Q: How does the pulsatile GH secretion pattern achieved with tesamorelin differ from exogenous GH therapy?

A: Tesamorelin stimulates the pituitary to amplify the amplitude of endogenous GH pulses while preserving the natural ultradian rhythm (6–10 pulses per 24 hours). Exogenous recombinant human GH (rhGH) administration, by contrast, delivers a sustained, supraphysiological GH level that bypasses hypothalamic-pituitary feedback regulation. Pulsatile GH is more effective than continuous GH in stimulating hepatic IGF-1 production and lipolysis at equivalent total GH exposure, while being less likely to cause hyperglycemia, fluid retention, and joint discomfort. Additionally, pulsatile GH maintains hepatic GH receptor expression, whereas continuous GH infusion downregulates GHR through ligand-induced receptor internalization — a mechanism that may contribute to reduced responsiveness with prolonged rhGH therapy.

Q: What is the mechanism by which tesamorelin reduces hepatic steatosis?

A: In the landmark trial by Stanley and colleagues, tesamorelin reduced hepatic fat content by 37% over 12 months in HIV patients with NAFLD. The mechanism involves: (1) direct hepatocyte effects — GH receptor activation stimulates mitochondrial fatty acid β-oxidation, increases VLDL secretion (exporting triglycerides from the liver), and inhibits de novo lipogenesis through suppression of SREBP-1c and ChREBP transcription factors; (2) indirect metabolic effects — reduced visceral adipose tissue lipotoxicity (decreased portal free fatty acid flux to the liver) and improved systemic insulin sensitivity; and (3) anti-inflammatory effects — reduced hepatic expression of pro-inflammatory cytokines and chemokines. Crucially, the liver fat reduction was statistically independent of changes in VAT, indicating a direct hepatic action of GH axis stimulation.

Q: What evidence supports tesamorelin's effects on non-alcoholic fatty liver disease (NAFLD/MASH)?

A: The evidence base includes: (1) a 2019 randomized placebo-controlled trial demonstrating 37% relative reduction in hepatic fat (¹H-MRS) with significant ALT reduction; (2) a 2020 follow-up study by Fourman and colleagues showing improvement in fibrosis markers (FIB-4 index, NAFLD fibrosis score) in addition to steatosis reduction; (3) mechanistic studies demonstrating GH receptor-mediated stimulation of hepatic fatty acid oxidation and inhibition of de novo lipogenesis; and (4) proof-of-concept data in non-HIV populations with NAFLD suggesting the effect is not HIV-specific. However, histological confirmation through liver biopsy in phase III MASH trials is necessary to confirm effects on steatohepatitis and fibrosis — the clinically meaningful endpoints for MASH therapeutics.

Q: What are the limitations and future directions for tesamorelin research?

A: Key limitations and future directions include: (1) requiring histological confirmation of hepatic benefits in MASH through dedicated phase III trials with liver biopsy endpoints; (2) need for long-term safety data beyond 52 weeks, particularly regarding effects on glucose homeostasis, IGF-1-related malignancy risk (theoretical, based on epidemiological associations between elevated IGF-1 and certain cancers), and cardiovascular outcomes; (3) investigation in broader populations beyond HIV — including general obesity, growth hormone deficiency, and metabolic syndrome cohorts; (4) exploration of cognitive benefits building on preclinical and early clinical evidence that GHRH analogs enhance cognitive function; (5) investigation of synergy with other metabolic peptides — GLP-1 agonists, GIP agonists, and glucagon receptor modulators — for combined metabolic and body composition effects; and (6) addressing the daily injection burden, a limitation relative to once-weekly metabolic peptide therapeutics.

References

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072664
2. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on liver fat and metabolic indices in HIV-associated NAFLD. J Clin Endocrinol Metab. 2019;104(9):4001-4010. doi:10.1210/jc.2019-00664
3. Fourman LT, Stanley TL, Zheng I, et al. Effect of tesamorelin on hepatic steatosis and fibrosis in HIV-associated NAFLD. Hepatology. 2020;71(6):1975-1987. doi:10.1002/hep.31013
4. Falutz J, Potvin D, Mamputu JC, et al. Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation. AIDS. 2008;22(13):1665-1676. doi:10.1097/QAD.0b013e3283030d91
5. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. AIDS. 2014;28(9):1299-1307. doi:10.1097/QAD.0000000000000256
6. Makimura H, Feldpausch MN, Stanley TL, et al. Tesamorelin reduces visceral adiposity in growth hormone-deficient adults. J Clin Endocrinol Metab. 2018;103(5):1853-1861. doi:10.1210/jc.2017-02729
7. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278. doi:10.1038/300276a0
8. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. doi:10.2165/11207480-000000000-00000
9. Mamputu JC, Marsolais C, Beaubien D, et al. Pharmacokinetics and pharmacodynamics of tesamorelin in HIV patients. J Clin Pharmacol. 2009;49(7):814-822. doi:10.1177/0091270009335456
10. Grunfeld C, Dobs AS, Engelson E, et al. Effects of tesamorelin on visceral adiposity in HIV-infected patients with abdominal fat accumulation. J Clin Endocrinol Metab. 2009;94(11):4286-4294. doi:10.1210/jc.2009-1330
11. Koutkia P, Canavan B, Breu J, et al. Growth hormone-releasing hormone (GHRH) administration in HIV-infected men: effects on body composition. J Clin Endocrinol Metab. 2005;90(5):2795-2800. doi:10.1210/jc.2004-2099
12. Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest. 2003;26(9):799-813. doi:10.1007/BF03345229
13. Lo J, You SM, Liebau J, et al. Effects of tesamorelin on coronary vascular function in HIV-infected patients. HIV Med. 2016;17(8):580-588. doi:10.1111/hiv.12381
14. Suh HS, Zhao Y, Smith N, et al. Tesamorelin for HIV-associated lipodystrophy: a systematic review. Clin Ther. 2014;36(10):1509-1522. doi:10.1016/j.clinthera.2014.08.004
15. Mayo KE, Miller T, DeAlmeida V, et al. The growth-hormone-releasing hormone receptor: signal transduction, gene expression, and physiological function in growth regulation. Recent Prog Horm Res. 1996;51:171-196. PMID: 8701079

About RPL Peptide: RPL Peptide is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers requiring certified reference materials for laboratory investigations, visit rplpeptides.com or explore detailed molecular data at the RPL Peptide Data Center.

— Written by the RPL Scientific Editorial Team | Last updated August 2025

Related Articles: Ipamorelin Research Profile | Metabolic Research | GLP-1 Peptide Research Overview | RPL Peptide | Peptide Research Data